Skip to main content
PMC home page
PLOS ONE logoLink to PLOS ONE
. 2022 Apr 5;17(4):e0266245. doi: 10.1371/journal.pone.0266245

Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials

Farah Yasmin 1, Hala Najeeb 1, Abdul Moeed 1, Wardah Hassan 1, Mahima Khatri 1, Muhammad Sohaib Asghar 2, Ahmed Kunwer Naveed 1, Waqas Ullah 3, Salim Surani 4,5,*
Editor: Tariq Jamal Siddiqi6
PMCID: PMC8982874  PMID: 35381033

Abstract

Background

Colchicine has been used an effective anti-inflammatory drug to treat gout diseases. Owing to its pharmacodynamic of inhibiting interleukins, it has been repurposed to target the cytokine storm post-SARS-CoV-2 invasion. The goal of this meta-analysis was to evaluate the safety profile of colchicine in COVID-19 patients using the gold-standard randomised-control trials.

Methods

Electronic databases (Pubmed, Google Scholar, and Cochrane) were systematically searched until June 2021 and RCTs were extracted. Outcomes of interest included all-cause mortality, COVID-19 severity, mechanical ventilation, C-reactive protein and D-dimer levels. Using a random-effects model, dichotomous outcomes were pooled using odds ratios (OR) through the generic inverse variance formula while weighted mean differences were calculated using the Wan’s method. P-values < 0.05 were considered statistically significant for all outcomes.

Results

A total population of 16,048 from five RCTs were included in the analysis. Of this, 7957 were randomized to colchicine, and 8091 received standard care, with an average age of 60.67 years. Colchicine was observed to significantly reduce COVID-19 severity (OR: 0.41, 95% CI [0.22, 0.76]; p = 0.005), and CRP levels (WMD: -19.99, 95% CI [-32.09, -7.89]; p = 0.001). However, there was no significant difference in D-dimer levels (WMD: 0.31, 95% CI [-0.61, 1.23]; p = 0.51), mechanical ventilation (OR: 0.42, 95% CI [0.17, 1.03]; p = 0.06; I2 = 74%) and all-cause mortality (OR: 0.98, 95% CI [0.83, 1.16]; p = 0.84) among patients receiving colchicine or standard care.

Conclusion

Colchicine treatment decreased CRP levels and COVID-19 severity, with dimer levels, all-cause mortality and mechanical ventilation remaining seemingly unaffected. Thus, clinical trials need to be carried out that allow effective evaluation of colchicine in COVID-19 patients.

Introduction

Coronavirus disease-19 (COVID-19) caused by the SARS-CoV-2 has piqued the interest of scientists and researchers worldwide. The disease carriers a mortality rate of 2.6% with the infection categorized into three phases namely initiation, pulmonary, and hyper-inflammatory according to increasing intensity. Each stage has its specified treatment, while antivirals and immuno-modulators are the preferred remedies of the first two stages [1–4]. Anti-inflammatory drugs are administered to curb the hyper-inflammatory state associated with increased C-reactive protein, pro-inflammatory cytokines, and chemokines in severe COVID-19 patients [5–7]. Due to its anti-inflammatory mechanisms, colchicine is suggested by experts as a potential treatment of the "cytokine storm" ensued by the aforementioned hyper-inflammation [8–10]. Randomized controlled trials (RCTs) are underway, testing the association of colchicine and COVID-19 adverse events, whereas numerous RCTs have already been carried out, COLCORONA and RECOVERY being the larger ones. Due to the inclusion of biased observational studies and small-moderate-sized RCTs, previous meta-analyses were of low statistical power. Thus, we conducted a systematic review and meta-analysis pooling all RCTs including the larger COLCORONA and RECOVERY trials to show a holistic and comprehensive clinical evaluation of the efficacy of colchicine in COVID-19. Furthermore, this study incorporates C-reactive protein (CRP) and D-dimer levels, which play a crucial role in assessing the severity of COVID-19, as their elevated levels are associated with a poor prognosis [11,12]. Moreover, CRP being a cardinal marker of inflammation, serves as an indicator of the potency of colchicine in SARS-CoV-2 infection [13].

Materials and methods

Search strategy and study selection

This study was carried out along the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines statement. [14] A comprehensive search was performed on PubMed (Medline), and Cochrane from the time of inception till June 12th, 2021. ClinicalTrials.gov, Google Scholar, and Medrxiv were searched to identify grey literature and preprints. Medical Subject Headings (MESH terms) and keywords were used to develop a search strategy which included [‘Coronavirus’ OR ‘COVID-19’ OR ‘SARS-CoV-2’] AND [‘Colchicine’]. S1 Table gives details of the search strategy. No filters or limitations were applied to the search results. Non-English language text was translated using the translate tool on Google. Hand-searching of review articles was performed to extract relevant studies. Two reviewers (FY and HN) independently screened titles, full texts, and abstracts of studies. Relevant studies were imported to Endnote X9 (Clarivate Analytics, US) to further remove duplicates.

Eligibility criteria

Studies included were selected based on the following: patient population, intervention, comparison, outcomes of interest, study design, and definition.

  1. Patient population: confirmed COVID-19 patients with a positive PCR test.

  2. Exposure: Patients who received colchicine

  3. Comparison: This includes the non-colchicine group which received the usual standard of care or placebo.

  4. Outcomes of interest: COVID-19 severity, all-cause mortality, mechanical ventilation, and the change in lab parameters pre-treatment, and post-treatment (D-dimer and Creatine reactive protein levels).

  5. Study design: Eligible completed randomized clinical trials were extracted to perform the meta-analysis.

Observational studies, case reports, and reviews were excluded from the meta-analysis at screening. Additionally, studies with non-human participants, children <18 years, or pregnant women were not included for analysis.

Data extraction

Two reviewers (FY and HN) extracted studies based on title, full text, and abstract. Data were extracted according to the following fields of interest: author, year of publication, study design, sample size, age of the participants, gender, proportion of participants in colchicine and control groups, colchicine dosage, follow-up time, effect sizes, and ratios (OR, HR or RR) along with 95% confidence intervals, and the median values with their interquartile ranges of D-dimer and CRP levels. S2 Table shows the baseline characteristics of patients. Additionally, data for the proportion of patients in each group who received mechanical ventilation post-treatment witnessed disease progression to severe COVID-19 or lost their lives were documented. COVID-19 severity was defined as per the official guidelines, as (1) respiratory rate of ≥30 breaths per min; (2) oxygen saturation at rest ≤93%; (3) ratio of the partial pressure of arterial oxygen (PaO2) to a fractional concentration of oxygen inspired air (fiO2) ≤300 mmHg; (4) lung infiltrates >50% or (5) critical complication (respiratory failure, septic shock, and or multiple organ dysfunction/failure) [15].

Study quality assessment

Two investigators (FY and HN) independently assessed the quality of clinical trials using the Revised Cochrane risk-of-bias tool for randomized trials (RoB 2) [16]. Studies were analyzed for generation of allocation sequence, randomisation of participants to exposure, selective reporting of outcomes, and missing data.

Statistical analysis

The present meta-analysis was performed using Review Manager 5.4 (Cochrane Collaboration) software. For dichotomous outcomes, odds ratios (ORs) and relative risks (RRs) along with their 95% CI were extracted. In the case of raw data availability, ORs were calculated. Median values along with interquartile ranges were reported for continuous outcomes: D-Dimer and CRP levels. These values were converted to mean and standard error using Wan’s method [17]. This meta-analysis reports a pooled effect of ORs and weighted mean differences (WMDs) using the generic-inverse variance and continuous outcome functions with a random-effects model. Each effect size was reported on a log scale, and the 95% CI was converted to standard error to normalize data distribution. All p values of < 0.05 was considered as statistically significant [17].

Heterogeneity amongst studies was assessed using the I2 statistics and it is reported as percentages [18]. A value of 25% was considered low heterogeneity, 25% - 50% was moderate, while an I2 value > 50% qualified for high discrepancy. Outcomes with studies that reported a high percentage of heterogeneity were subjected to sensitivity analysis to explore the effect of each study on the pooled estimate. According to Cochrane’s guidelines [18], since data for at least 10 studies was unavailable, a funnel plot could not be obtained to detect publication bias.

Results

Study selection and characteristics

The search results yielded a total of 1152 studies, of which 989 results were screened after removing duplicates, as shown in Fig 1. 21 studies were screened for full text. Of these, seven studies were identified as case series, observational, and reviews, four studies assessed the effects of combination therapy while five studies were excluded because they did not report complete results of interest. Five randomized-controlled trials, Lopes et al. [19], COLCORONA [20], GRECCO [21], RECOVERY [22], and COLORIT [23] were selected for qualitative analysis. Meta-analysis was performed on a total population of 16,048 COVID-19 positive patients. Characteristics of all included RCTs are present in Table 1.

Fig 1. PRISMA flow chart.

Fig 1

Open in a new tab

Table 1. Study characteristics of included studies.

Author, year Study type Sample size, N Patient Population Average age, years Male Sex, n (%) Treatment duration, days Intervention and dosage
Treatment Control
Mareev et al, 2021 [23] RCT 43 COVID-19 61.9 (10.6) 59.9 (18.8) 30 (69.8) 13 (3.2) 1 mg during the first 1–3 days followed by 0.5 mg/day
Holby et al, 2021 [22] RCT 11340 COVID-19 within 24h 63.3 (13.8) 63.5 (13.7) 5609 (49.4) 28 N/A
Tardif et al, 2021 [20] RCT 4488 COVID-19 within 24 h of enrolment 53·7 (10.4) 54·0 (10.4) 2067 (46.1) 30 0·5 mg orally administered twice per day for the first 3 days and then once per day for 27 days
Deftereos et al, 2020 [21] RCT 105 Hospitalized with COVID-19 59.7 (4.6) 62.7 (11.4) 61 (58.1) 21 1.5-mg loading dose followed by 0.5 mg after 60 min and maintenance doses of 0.5 mg twice daily) with standard medical treatment for as long as 3 weeks
Lopes et al, 2021 [19] RCT 72 Moderate-severe COVID-19 53.8 (17.0) 54.7 (19.3) 35 (48.6) 7.0 (3.0) 0.5 mg thrice daily for 5 days, then 0.5 mg twice daily for 5 days; if bodyweight ≥80 kg, the first dose was 1.0 mg
Open in a new tab

COVID-19 severity

Three out of five studies assessed COVID-19 severity based on the above-mentioned criteria. Colchicine was shown to significantly reduce COVID-19 severity [OR = 0.41; 95% CI: 0.22–0.76, p-value 0.005; I2 0%] compared to the control as shown in Fig 2.

Fig 2. Association of COVID-19 severity in colchicine users.

Fig 2

Open in a new tab

Red squares and their corresponding lines are the point estimates and 95% confidence intervals per each study. Black diamonds represent the pooled effect estimate.

All-cause mortality

All-cause mortality was reported in all five studies included. There was no significant difference in all-cause mortality [OR = 0.98; 95% CI: 0.83–1.16, p-value 0.84; I2 0%] among patients randomized to colchicine or standard care as demonstrated in Fig 3. No in-study heterogeneity was appreciated.

Fig 3. Forest plot for the effect of colchicine on COVID-19 patients.

Fig 3

Open in a new tab

Red squares and their corresponding lines are the point estimates and 95% confidence intervals per each study. Black diamonds represent the pooled effect estimate.

Mechanical ventilation

Of the four studies included in quantitative analysis, there was no statistically significant reduction in mechanical ventilation [OR = 0.42; 95% CI: 0.17–1.03, p = 0.06] among patients randomized to colchicine vs. standard care, as shown in Fig 4. These results were subjected to a moderately-high heterogeneity (I2 74%; p-value 0.008).

Fig 4. Forest plot for effects of colchicine on mechanical ventilation in COVID-19 patients.

Fig 4

Open in a new tab

Blue squares and their corresponding lines are the point estimates and 95% confidence intervals per each study. Black diamonds represent the pooled effect estimate.

Leave-one-out sensitivity analysis

Excluding the trials one-by-one from the pooled analysis did not reduce the in-study heterogeneity [I2 44%; p-value 0.17]. However, patients receiving colchicine had significantly lower odds of mechanical ventilation [OR = 0.26; 95% CI: 0.08–0.77, p-value 0.02] compared to standard care upon exclusion of the RECOVERY trial [22] as depicted in Fig 5.

Fig 5. Forest plot for leave-one-out sensitivity analysis of colchicine on mechanical ventilation in COVID-19 patients.

Fig 5

Open in a new tab

Blue squares and their corresponding lines are the point estimates and 95% confidence intervals per each study. Black diamonds represent the pooled effect estimate.

D-Dimer level

The COLORIT and GRECCO-19 trials were pooled to determine the effect on D-dimer inflammatory marker as shown in Fig 6. There was no significant difference in D-dimer levels among patients randomized to colchicine or standard care (p = 0.99). Moreoever, patients randomized to colchicine demonstrated a non-significant elevation of D-dimer levels post-treatment [WMD = 0.3, 95%CI:-0.61–1.23; p = 0.51].

Fig 6. Forest plot for effects of colchicine on D-Dimer in COVID-19 patients.

Fig 6

Open in a new tab

Green squares and their corresponding lines are the point estimates and 95% confidence intervals per each study. Black diamonds represent the pooled effect estimate.

C-Reactive Protein (CRP) level

Colchicine was observed to significantly decrease mean CRP levels post-treatment [WMD = -19.99; 95% CI: -32.09 to -7.89, p-value 0.001; I2 98%]. On the contrary, COVID-19 patients on standard control therapy showed no reduction in mean CRP levels [WMD = 2.16; 95% CI: -7.59 to 11.92), p-value 0.66; I2 95%]. The forest plots for both analyses are shown in Fig 7.

Fig 7. Forest plot for effects of colchicine on CRP levels in COVID-19 patients.

Fig 7

Open in a new tab

Green squares and their corresponding lines are the point estimates and 95% confidence intervals per each study. Black diamonds represent the pooled effect estimate.

Risk of bias of included studies

Owing to the robust methodology of the included clinical trials, evaluation with the Revised Cochrane Risk of Bias tool (ROB 2) demonstrated a low risk of bias in all included studies. The results of the quality assessment are summarized in Fig 8.

Fig 8. Quality assessment of RCTs using revised cochrane risk-of-bias tool.

Fig 8

Open in a new tab

Discussion

Our meta-analysis of five RCTs, in summary, testified to the following key findings: i) treatment with colchicine was associated with a significant reduction in the severity of COVID-19 ii) CRP levels were significantly lower in patients treated with colchicine compared to the control group. Data from multiple studies suggest an active role of Cytokine Release Syndrome (CRS) in developing ARDS and lung failure due to COVID-19 [24–26]. Based on the assumption that a ‘cytokine storm’ drives the progression of the disease, the anti-interleukin-6 receptor monoclonal antibody tocilizumab has been used worldwide to treat this deadly virus [27]. However, it has been suggested that there may be a ‘window of opportunity’ for down-modulating the immune response against the virus, without preventing its clearance [28]. In this context, colchicine, an old anti-inflammatory drug, may play a role in reversing the disease course of COVID-19.

Considerable studies have advocated that colchicine has a favorable role in treating COVID-19 [29,30]. Colchicine binds irreversibly to alpha/beta dimers and blocks the extension of microtubules. Microtubules are imperative for the migration of neutrophils towards the inflammatory focus. In addition to this, it inhibits the interaction between neutrophils and endothelial cells by altering the number and distribution of selectins, thus decreasing E-selectin-mediated adhesiveness between endothelial cells and neutrophils [31]. Studies suggest that neutrophils play an essential role in developing CRS [32]. Thus, the inhibitory effects of colchicine on neutrophil motility, adhesiveness, and chemotaxis prevent the incidence of CRS and reduce the COVID-19 severity. Likewise, it has been found that inhibition of tubulin ligands by colchicine also inhibits the replication of viruses that depends on the microtubule network [31]. At last, colchicine can also inhibit the activation of the NLRP3 inflammasome. Interruption of inflammasome activation will reduce IL-1β production, which in turn prevents the induction of IL-6 and TNF-α and the recruitment of additional neutrophils and macrophages [33].

Our study shows that treatment with Colchicine was associated with a significant abatement in the severity of COVID-19 infection contrasted to the control group. This finding is coherent with the results of a meta-analysis by Timotius Ivan Hariyanto et al. [34]. It has been found that elevated levels of cytokines may cause extensive lung consolidation, which has been observed in the case of severe COVID-19 [35]. Thus, colchicine action in reducing the pro-inflammatory cytokines can alter the severity of COVID-19.

Pooling of the RCTs demonstrated that treatment with colchicine was not associated with a significant reduction in the all-cause mortality due to COVID-19 contrasted to the control group. The previous meta-analysis by Hariyanto et al. [34] exhibited a significant reduction in all-cause mortality. This difference in results could be due to the limited number of studies reporting this outcome. The inhibition of neutrophil adhesiveness and chemotaxis and replication of viruses curtails the incidence of CRS, thus forestalling the development of host autoimmune inflammatory response, which damages multiple organ systems, increasing the risk of mortality. The study by Mirko Scarsi et al. [36] endorses the idea that the prevention of the development of host autoimmune inflammatory responses causes a significant reduction in mortality rate.

Three out of five RCTs incorporated in this meta-analysis showed a significant contraction in need for mechanical ventilation with treatment with colchicine, whereas the RECOVERY trial [34] did not show a significant reduction. Reduction in the rates of COVID-19 induced lung fibrosis due to anti-inflammatory effects of colchicine [35] explains the decreased need for mechanical ventilation in the colchicine group. Owing to a limited number of studies assessing the effect of colchicine on the need for ventilation, the legitimacy of this reduced incidence cannot be counted on. Therefore, more studies should be directed towards scrutinizing the effects of Colchicine on the need for mechanical ventilation.

As per the analysis of COLORIT and GRECCO-19 trials, the colchicine group experienced slight elevation in the D-Dimer levels. A plausible reason for this outcome can be the anti-inflammatory and antithrombotic properties of colchicine on the endothelium as studied by Shiffman et al. in his study regarding Familial Mediterranean Fever [37]. D-dimer itself is a plasmin-mediated, proteolytic degradation product of cross-linked fibrin [38], which generally increases during any clinical condition; simultaneously, both clot formation and fibrinolysis occur. Direct endothelial injury in COVID-19 patients caused by inflammatory cytokines resulted in hypercoagulability, leading to increased D-dimer levels [39]. Colchicine plays a vital role in impaiing neutrophils’ adhesion to the vascular endothelium; thereby, diminishing the endothelial selectin family-dependent adhesiveness [40]. Furthermore, colchicine blocked pro-inflammatory cytokines such as IL-1β, TNF-α, NF-κ, and NLRP3 inflammasome, leading to a reduction in the inflamed area and an overall decrease in the severity of the disease [41]. The individual trial of GRECCO-19 [21] depicted a decrease in the levels of risk markers of thrombotic complications, such as D-dimer and fibrinogen dropped to almost upper normal in the colchicine group; however, these decreases did not reach significance. Conversely, the COLORIT trial [23] displayed an increase in the d-dimer levels in the colchicine group versus the control group, possibly because of the activation of hypoxia-responsive signalling pathways, which further led to increased thrombogenicity [42] mainly in COVID-19 with poor prognosis [43,44]. The discrepancy in results can be explained by the involvement of only two trials in assessing the role of colchicine on D-dimer levels in COVID-19 patients and using a high loading dose of colchicine used in the COLORIT trial as compared to the GRECCO-19 trial. Therefore, in the future, large multi-center trials can display more coherent results regarding this subject.

CRP, an acute-phase reactant produced by the liver in response to inflammation, is markedly elevated in COVID-19 patients [45]. The levels of CRP fluctuate with the severity of the said disease. Therefore, it is proven to be a reliable predictor of cytokine release syndrome [46]. Extremely high CRP levels in COVID-19 patients are directly linked to poor prognosis. Our study’s pooling of three RCTs delineated a significant decrease in the CRP levels in COVID-19 patients taking colchicine instead of standard therapy. This outcome highlights the role of colichine in forming tubulin-colchicine complexes leading to its anti-inflammatory effects of inhibiting chemotaxis, motility, and adhesion of neutrophils, interfering in superoxide production and inhibiting tumor necrosis factor leading to an overall decrease in cytokine storm in COVID-19 patients [47]. In the later stages of infection, intracellular viral transport and protein trafficking are mediated by microtubules; colchicine binding to the microtubule inhibits coronavirus’s function and the tendency to enter the host cell [48]. A reduction in viral load is associated with decreased secreted pro-inflammatory mediators and a cumulative decrease in CRP levels.

It has been suggested that colchicine also plays a key role in destabilization and degradation of NLPR3 inflammasome leading to decreased IL-1β mediated synthesis of IL-6. In response to decreased IL-6 stimulation, the liver automatically diminishes CRP release [49], proving our study findings align with the latest review published by Reyes et al. regarding anti-inflammatory therapy for COVID-19 infection [50]. This study has several strengths. Firstly, it includes all gold-standard RCTs that largely prove the safety and efficacy of Colchicine as an anti-inflammatory medication for different inflammatory conditions, including COVID-19. We have also included the findings of recent large-scale RECOVERY trial that contributed to the estimates in our study, and concluded that Colchicine has no significant effect on all-cause mortality and mechanical ventilation. Hence, our study expands the findings of prior literature by including contemporary trials that were missed by previous meta-analyses. The pooled estimates of prior meta-analyses were largely driven by non-randomized observational data leading to conflicting findings, the conclusion of our meta-analysis (based on only RCTs) bring consensus on the utility of Colchicine in these patients. Other reason being all included studies had some concern for risk of bias in all previous meta-analyses. Secondly, our meta-analysis comprising of only RCTs includes a summary of 16,048 COVID-19 positive patients indicating higher statistical power in comparison to previous meta-analyses. Lastly, we have demonstrated a higher methodological quality of the included trials using the standard recommended ROB-2 approach, to ensure the quality of data for inclusion of studies in our meta-analysis model. Given this, we believe our large-scale meta-analysis could serve as a benchmark against which the findings of individual studies and future trials could be compared.

Limitations

The analysis includes a limited number of randomized controlled trials, which can lead to inadequate evidence of results with an overall increase in the risk of bias. Additionally, the duration of colchicine therapy was not entirely uniform in all the RCTs, possibly contributing to the differed results. Different dosage and the duration of the loading dose and overall length of therapy presents as a limitation of this study. Due to the low number of studies per outcome and limited available data, a sensitivity analysis was performed in place of subgroup analysis to assess high heterogeneity.

Conclusion

Colchicine administration can be a breakthrough in the treatment of COVID-19 patients as it reduces overall disease severity. Therefore, clinicans should consider usage of colchicine in COVID-19 patients in combination or as a monotheraphy to reduce disease severity. Lastly, taking into consideration the adverse effects of colchicine in the disease prognosis, more clinical trials shall be conducted in the near future to effectively assess the efficacy and the safety of colchicine in COVID-19 patients.

Supporting information

S1 Checklist. PRISMA 2020 checklist.

(DOCX)

Click here for additional data file. (31.8KB, docx)
S1 Table. Detailed search strategy.

(DOCX)

Click here for additional data file. (14.8KB, docx)
S2 Table. Baseline characteristics of patients included in each study.

(DOCX)

Click here for additional data file. (17.4KB, docx)

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.“Timeline of WHO’s response to COVID-19”.
  • 2.“WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data.” https://covid19.who.int/ (accessed Jun. 08, 2021).
  • 3.“Novel 2019 coronavirus genome—SARS-CoV-2 coronavirus—Virological”.
  • 4.Miller I. F., Becker A. D., Grenfell B. T., and Metcalf C. J. E., “Disease and healthcare burden of COVID-19 in the United States,” Nat. Med., vol. 26, no. 8, pp. 1212–1217, Aug. 2020, doi: 10.1038/s41591-020-0952-y [DOI] [PubMed] [Google Scholar]
  • 5.Guan W. et al. , “Clinical Characteristics of Coronavirus Disease 2019 in China,” N. Engl. J. Med., vol. 382, no. 18, pp. 1708–1720, Apr. 2020, doi: 10.1056/NEJMoa2002032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Turk C., Turk S., Malkan U. Y., and Haznedaroglu I. C., “Three critical clinicobiological phases of the human SARS-associated coronavirus infections,” Eur. Rev. Med. Pharmacol. Sci., vol. 24, no. 16, pp. 8606–8620, 2020, doi: 10.26355/eurrev_202008_22660 [DOI] [PubMed] [Google Scholar]
  • 7.Qin C. et al. , “Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China,” Clin. Infect. Dis., vol. 71, no. 15, pp. 762–768, Aug. 2020, doi: 10.1093/cid/ciaa248 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Leung Y. Y., Yao Hui L. L., and Kraus V. B., “Colchicine-Update on mechanisms of action and therapeutic uses,” Seminars in Arthritis and Rheumatism, vol. 45, no. 3. W.B. Saunders, pp. 341–350, Dec. 2015, doi: 10.1016/j.semarthrit.2015.06.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Fajgenbaum D. C. and June C. H., “Cytokine Storm,” N. Engl. J. Med., vol. 383, no. 23, pp. 2255–2273, Dec. 2020, doi: 10.1056/NEJMra2026131 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Le R. Q. et al. , “FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome,” Oncologist, vol. 23, no. 8, pp. 943–947, Aug. 2018, doi: 10.1634/theoncologist.2018-0028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Yao Y. et al. , “D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case control study,” J. Intensive Care, vol. 8, no. 1, pp. 1–11, Jul. 2020, doi: 10.1186/s40560-020-00466-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Ali N., “Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19,” Journal of Medical Virology, vol. 92, no. 11. John Wiley and Sons Inc, pp. 2409–2411, Nov. 2020, doi: 10.1002/jmv.26097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Sproston N. R. and Ashworth J. J., “Role of C-reactive protein at sites of inflammation and infection,” Frontiers in Immunology, vol. 9, no. APR. Frontiers Media S.A., p. 754, Apr. 2018, doi: 10.3389/fimmu.2018.00754 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Liberati A. et al. , “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.,” BMJ, vol. 339, Jul. 2009, doi: 10.1136/bmj.b2700 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.“Clinical Spectrum | COVID-19 Treatment Guidelines.” https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/ (accessed Jun. 18, 2021).
  • 16.Sterne J. A. C. et al. , “RoB 2: A revised tool for assessing risk of bias in randomised trials,” BMJ, vol. 366, Aug. 2019, doi: 10.1136/bmj.l4898 [DOI] [PubMed] [Google Scholar]
  • 17.Wan X., Wang W., Liu J., and Tong T., “Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range,” BMC Med. Res. Methodol., vol. 14, no. 1, p. 135, Dec. 2014, doi: 10.1186/1471-2288-14-135 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Higgins J. P. T., Thompson S. G., Deeks J. J., and Altman D. G., “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414. BMJ Publishing Group, pp. 557–560, Sep. 06, 2003, doi: 10.1136/bmj.327.7414.557 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Lopes M. I. et al. , “Beneficial effects of colchicine for moderate to severe COVID-19: A randomised, double-blinded, placebo-controlled clinical trial,” RMD Open, vol. 7, no. 1, Feb. 2021, doi: 10.1136/rmdopen-2020-001455 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Tardif J.-C. et al. , “Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial,” Lancet Respir. Med., May 2021, doi: 10.1016/S2213-2600(21)00222-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Deftereos S. G. et al. , “Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized with Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial,” JAMA Netw. Open, vol. 3, no. 6, Jun. 2020, doi: 10.1001/jamanetworkopen.2020.13136 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Landray M., “Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial,” medRxiv, p. 2021.05.18.21257267, May 2021, doi: 10.1101/2021.05.18.21257267 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Mareev V. Y. et al. , “Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study,” Kardiologiya, vol. 61, no. 2, pp. 15–27, 2021, doi: 10.18087/cardio.2021.2.n1560 [DOI] [PubMed] [Google Scholar]
  • 24.COVID- 19: consider cytokine storm syndromes and immunosuppression. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, HLH Across Speciality Collaboration UK. Lancet. 2020; 395:1033–1034. doi: 10.1016/S0140-6736(20)30628-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.IL-6 Inhibitors in the treatment of serious COVID- 19: a promising therapy? Atal S, Fatima Z. Pharmaceut Med. 2020;34:223–231. doi: 10.1007/s40290-020-00342-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Rational use of tocilizumab in the treatment of novel coronavirus pneumonia. Zhang S, Li L, Shen A, Chen Y, Qi Z. Clin Drug Investig. 2020; 40:511–518. doi: 10.1007/s40261-020-00917-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Zhang C, Wu Z, Li J-W, et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents 2020; 55:105954. doi: 10.1016/j.ijantimicag.2020.105954 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Ferro F, Elefante E, Baldini C, et al. COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol 2020; 38:175–80. [PubMed] [Google Scholar]
  • 29.Della-Torre E, Della-Torre F, Kusanovic M, et al. Treating COVID-19 with colchicine in community healthcare setting. Clin Immunol. 2020; 217:108490. doi: 10.1016/j.clim.2020.108490 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Schlesinger N, Firestein BL, Brunetti L. Colchicine in COVID-19: an old drug, new use. Curr Pharmacol Rep. 2020; 6:137–145. doi: 10.1007/s40495-020-00225-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Schlesinger N, Firestein BL, Brunetti L. Colchicine in COVID-19: an old drug, new use. Curr Pharmacol Rep. 2020; 6:137–145. 25. doi: 10.1007/s40495-020-00225-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Li X, Liu C, Mao Z, et al. Predictive values of neutrophil to lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis. Crit Care. 2020;24(1):647. doi: 10.1186/s13054-020-03374-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Reyes AZ, Hu KA, Teperman J, et al. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. Ann Rheum Dis. 2020. doi: 10.1136/annrheumdis-2020-219174 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Hariyanto TI, Halim DA, Jodhinata C, Yanto TA, Kurniawan A. Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Clin Exp Pharmacol Physiol. 2021; 48:823–830. doi: 10.1111/1440-1681.13488 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Della-Torre E, Campochiaro C, Cavalli G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020;79(10):1277–1285. doi: 10.1136/annrheumdis-2020-218122 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Scarsi M., Piantoni S., Colombo E., Airó P., Richini D., Miclini M., et al. (2020). Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. Annals of the Rheumatic Diseases, annrheumdis–2020–217712. doi: 10.1136/annrheumdis-2020-217712 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Tayer-Shifman OE, Ben-Chetrit E. Familial Mediterranean fever and hypercoagulability. Mediterranean journal of hematology and infectious diseases. 2011;3(1). doi: 10.4084/MJHID.2011.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.D-dimer: establishing a laboratory assay for ruling out venous thrombosis. [PubMed]
  • 39.Notley C., Tinlin S., Sawyer L., Begbie M., and Lillicrap D., “The factor VIII acute phase response requires the participation of NFκB and C/EBP,” Thrombosis and Haemostasis, vol. 84, no. 8, pp. 216–222, 2000. [PubMed] [Google Scholar]
  • 40.Cronstein BN, Molad Y, Reibman J, et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995;96:994–1002. doi: 10.1172/JCI118147 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237–4. doi: 10.1038/nature04516 [DOI] [PubMed] [Google Scholar]
  • 42.Gupta N, Zhao Y-Y, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res. 2019;181:77–83. doi: 10.1016/j.thromres.2019.07.013 [DOI] [PubMed] [Google Scholar]
  • 43.Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. Published April 15, 2020. doi: 10.1016/j.jacc.2020.04.031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Marnell L, Mold C, Du Clos TW. C‐reactive protein: ligands, receptors, and role in inflammation. Clin Immunol. 2005;117(2):104‐111. doi: 10.1016/j.clim.2005.08.004 [DOI] [PubMed] [Google Scholar]
  • 46.Wang G, Wu C, Zhang Q, et al. C‐reactive protein level may predict the risk of COVID‐19 aggravation. Open Forum Infect Dis. 2020;7(5). doi: 10.1093/ofid/ofaa153 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Brunetti L, Diawara O, Tsai A, Firestein BL, Nahass RG, Poiani G, et al. Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19. Journal of clinical medicine. 2020. Sep;9(9):2961. doi: 10.3390/jcm9092961 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Greber U.F. Signalling in viral entry. Cell Mol. Life Sci. 2002;59:608–626. doi: 10.1007/s00018-002-8453-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Parra-Medina R., Sarmiento-Monroy J.C., Rojas-Villarraga A., Garavito E., Montealegre-Gomez G., Gomez-Lopez A. Colchicine as a possible therapeutic option in COVID-19 infection. Clin. Rheumatol. 2020;39:2485–2486. doi: 10.1007/s10067-020-05247-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Reyes AZ, Hu KA, Teperman J, Muskardin TL, Tardif JC, Shah B, et al. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. Annals of the rheumatic diseases. 2021. May 1;80(5):550–7. doi: 10.1136/annrheumdis-2020-219174 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Tariq Jamal Siddiqi

7 Dec 2021

PONE-D-21-32538Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trialsPLOS ONE

Dear Dr. Surani,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jan 21 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Tariq Jamal Siddiqi

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Additional Editor Comments:

Surani et al. conducted a meta-analysis on, “Safety and efficacy of colchicine in COVID-19 patients”, in which they reported that colchicine treatment decreased CRP levels and COVID-19 severity, with dimer levels, all-cause mortality and mechanical ventilation remaining seemingly unaffected. In my opinion, this study can be improved by incorporating the following points:

1. The strengths of the study are not clear, and it should be highlighted more as to what this study adds to the medical literature and how they address the current gap

2. The limitations may be somewhat enhanced further by highlighting additional limitations that resulted in study heterogeneity or why subgroup analysis was not performed.

3. Overall the quality of discussion is commendable, but it needs to proofread for example the capitalization error in line 281.

4. It can enhance the quality of results further if the number of studies that were included for mechanical ventilation and all-cause mortality was mentioned at the beginning of the paragraph.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Apr 5;17(4):e0266245. doi: 10.1371/journal.pone.0266245.r002

Author response to Decision Letter 0

3 Mar 2022

January 10th, 2022

Editor-in-Chief

PLOS-One

Dear Editor,

We are pleased to submit our revised manuscript entitled ‘Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials’ for consideration for publication in PLOS-One.

We appreciate the comments we received from the editors and reviewers, all of which have been addressed in this revised version of the paper. Please find below the editor’s and reviewer’s comments in bold and the author responses. We further ensure that the material has not and will not be offered elsewhere for possible publication, as it is under consideration.

We hope that these changes will make the manuscript competitive for publication in the journal.

Salim Surani, MD, MPH, MSHM, FACP, FCCP, FAASM

Adjunct Clinical Professor of Medicine and Pharmacology,

Texas A&M University, USA.

Clinical Professor, University of Houston (Voluntary

Email: salimsurani@gmail.com

You state: The strengths of the study are not clear, and it should be highlighted more as to what this study adds to the medical literature and how they address the current gap.

Response: Thank you so much for pointing this out. We have now edited the manuscript to include the following details:

This study has several strengths. Firstly, it includes all gold-standard RCTs that largely prove the safety and efficacy of Colchicine as an anti-inflammatory medication for different inflammatory conditions, including COVID-19. We have also included the findings of recent large-scale RECOVERY trial that contributed to the estimates in our study, and concluded that Colchicine has no significant effect on all-cause mortality and mechanical ventilation. Hence, our study expands the findings of prior literature by including contemporary trials that were missed by previous meta-analyses. The pooled estimates of prior meta-analyses were largely driven by non-randomized observational data leading to conflicting findings, the conclusion of our meta-analysis (based on only RCTs) bring consensus on the utility of Colchicine in these patients. Other reason being all included studies had some concern for risk of bias in all previous meta-analyses. Secondly, our meta-analysis comprising of only RCTs includes a summary of 16,048 COVID-19 positive patients indicating higher statistical power in comparison to previous meta-analyses. Lastly, we have demonstrated a higher methodological quality of the included trials using the standard recommended ROB-2 approach, to ensure the quality of data for inclusion of studies in our meta-analysis model. Given this, we believe our large-scale meta-analysis could serve as a benchmark against which the findings of individual studies and future trials could be compared.

You state: The limitations may be somewhat enhanced further by highlighting additional limitations that resulted in study heterogeneity or why subgroup analysis was not performed.

Response: Thank you so much for pointing this out. We have now edited the manuscript to include the following details:

Different dosage and the duration of the loading dose and overall length of therapy presents as a limitation of this study. Due to the low number of studies per outcome and limited available data, a sensitivity analysis was performed in place of subgroup analysis to assess high heterogeneity.

You state: Overall the quality of discussion is commendable, but it needs to proofread for example the capitalization error in line 281.

Response: Thank you for pointing this out. The manuscript has been proof-read and corrected for grammatical and spelling errors.

You state: It can enhance the quality of results further if the number of studies that were included for mechanical ventilation and all-cause mortality was mentioned at the beginning of the paragraph.

Response: Thank you so much for pointing this out. We have now edited the manuscript to include the following details:

All-cause mortality was reported in all five studies included.

And

Of the four studies included in quantitative analysis, there was no statistically significant reduction in mechanical ventilation.

Attachment

Submitted filename: Rebuttal Letter.docx

Click here for additional data file. (17KB, docx)

Decision Letter 1

Tariq Jamal Siddiqi

17 Mar 2022

Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials

PONE-D-21-32538R1

Dear Dr. Surani,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Tariq Jamal Siddiqi

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Acceptance letter

Tariq Jamal Siddiqi

28 Mar 2022

PONE-D-21-32538R1

Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials

Dear Dr. Surani:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Tariq Jamal Siddiqi

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. PRISMA 2020 checklist.

    (DOCX)

    Click here for additional data file. (31.8KB, docx)
    S1 Table. Detailed search strategy.

    (DOCX)

    Click here for additional data file. (14.8KB, docx)
    S2 Table. Baseline characteristics of patients included in each study.

    (DOCX)

    Click here for additional data file. (17.4KB, docx)
    Attachment

    Submitted filename: Rebuttal Letter.docx

    Click here for additional data file. (17KB, docx)

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.

    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES